Natalizumab Withdrawn Phase 4 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00771043A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a